Loading...
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
The development of bispecific antibodies that redirect the cytotoxic activity of CD3+ T cells to tumours is a promising immunotherapeutic strategy for the treatment of haematological malignancies and solid cancers. Since the landmark FDA approval at the end of 2014 of the anti-CD3 × anti-CD19 bispec...
Na minha lista:
| Udgivet i: | Br J Cancer |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7960983/ https://ncbi.nlm.nih.gov/pubmed/33469153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01225-5 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|